

DEVELOPMENT OF BIOCOMPOSITE SCAFFOLDS AND
INJECTABLE BIOCEMENT FOR BONE REGENERATION

Fan Wu

A thesis submitted for the degree of

Doctor of Philosophy

School of Chemical Engineering

The University of Adelaide

Australia

February 2013

Table of Contents

Abstract	viii
Declaration	xi
Acknowledgement	xii
List of Publications	xiii
List of Figures	xiv
List of Tables	xvii
List of Abbreviations	xviii
Chapter 1 Introduction	1
1.1 Background	1
1.2 Thesis aims	2
1.3 Scope of the thesis.....	3
Chapter 2 Literature review	5
2.1 Bone	5
2.2 Bone graft substitutes.....	6
2.3 Calcium phosphate cement (CPC).....	7
2.3.1 Formulations of CPC	7
2.3.2 The setting reaction of CPC	9
2.3.3 Biological properties of CPC	10
2.3.4 Clinical and medical applications of CPC	11
2.4 New developments in CPC	11
2.4.1 Injectable CPC	11
2.4.2 Premixed CPC.....	13
2.5 Bone tissue engineering scaffolds.....	15
2.5.1 Bone tissue engineering	15
2.5.2 Characteristics of an ideal tissue engineering scaffold	17
2.5.3 Scaffold materials.....	18

2.5.3.1	Ceramics.....	18
2.5.3.2	Natural polymers.....	19
2.5.3.3	Synthetic polymers.....	21
2.5.4	Composite scaffolds of PCL/natural polymer.....	24
2.5.4.1	PCL/starch composite scaffolds.....	24
2.5.4.2	PCL/chitosan composite scaffolds.....	25
2.5.4.3	PCL/collagen composite scaffolds.....	25
2.5.5	Composite scaffolds of PCL/ceramic.....	26
2.5.5.1	PCL/HA composite scaffolds.....	26
2.5.5.2	PCL/TCP composite scaffolds.....	27
2.5.5.3	PCL/bioactive glasses composite scaffolds.....	28
2.5.6	Zein.....	28
2.5.7	Magnesium phosphate cement.....	29
2.5.8	Processing techniques for composite scaffolds.....	30
2.6	The research gap.....	31
Chapter 3 Premixed, injectable PLA-modified calcium deficient apatite		
biocement (cd-AB) with washout resistance.....		
3.1	Introduction.....	33
3.2	Materials and methods.....	35
3.2.1	Cement powder and cement liquids.....	35
3.2.2	Evaluation of washout resistance.....	36
3.2.3	Setting time.....	37
3.2.4	Compressive strength.....	37
3.2.5	Analysis by XRD, FTIR and SEM.....	38
3.2.6	Injectability of the cement.....	39
3.2.7	<i>In vitro</i> degradation.....	39
3.2.8	<i>In vitro</i> cytocompatibility.....	40
3.2.8.1	Cell proliferation.....	40

3.2.8.2	Cell attachment.....	41
3.2.9	Statistical analysis	42
3.3	Results	42
3.3.1	Washout resistance	42
3.3.2	Setting time and compressive strength.....	42
3.3.3	Chemical compositions	45
3.3.4	Microstructural morphology	48
3.3.5	Injectability	48
3.3.6	<i>In vitro</i> degradability	51
3.3.7	Cytocompatibility.....	55
3.4	Discussion	58
3.5	Conclusion	63
Chapter 4	Fabrication and properties of porous scaffold of zein/PCL biocomposite for bone tissue engineering	65
4.1	Introduction	65
4.2	Materials and methods	67
4.2.1	Materials.....	67
4.2.2	Preparation of composite scaffolds	67
4.2.3	Scaffold characterization.....	68
4.2.3.1	Micro-CT analysis.....	68
4.2.3.2	Analysis by FTIR and SEM	69
4.2.3.3	Mechanical properties	69
4.2.3.4	Hydrophilicity	69
4.2.4	<i>In vitro</i> degradation	69
4.3	Results	70
4.3.1	SEM analysis.....	70
4.3.2	Micro-CT analysis.....	73
4.3.3	FTIR analysis	73

4.3.4	Mechanical properties	77
4.3.5	Hydrophilicity	77
4.3.6	<i>In vitro</i> degradation	77
4.4	Discussion	84
4.5	Conclusion.....	87
Chapter 5 Preparation and characterization of porous scaffold of magnesium phosphate/polycaprolactone biocomposite for bone tissue engineering.....		89
5.1	Introduction	89
5.2	Materials and methods	91
5.2.1	Materials.....	91
5.2.2	Preparation of composite scaffolds	91
5.2.3	Characterization	92
5.2.3.1	Micro-CT analysis.....	92
5.2.3.2	Analysis by XRD and SEM	93
5.2.3.3	Mechanical properties	93
5.2.3.4	Hydrophilicity	93
5.2.4	<i>In vitro</i> degradation study.....	94
5.3	Results	94
5.3.1	Micro-CT analysis.....	94
5.3.2	SEM analysis.....	99
5.3.3	XRD analysis.....	99
5.3.4	Mechanical properties	102
5.3.5	Hydrophilicity	102
5.3.6	<i>In vitro</i> degradation	105
5.4	Discussion	108
5.5	Conclusion.....	112
Chapter 6 Conclusion.....		113
6.1	Premixed and injectable calcium deficient apatite bio cement	113

6.2	Biocomposite scaffolds for bone tissue engineering.....	114
6.3	Future work.....	115
6.3.1	Future work regarding premixed and injectable cd-AB.....	115
6.3.2	Future work regarding the zein/PCL scaffolds	116
6.3.3	Future work regarding the PCL/MP scaffolds	117
Chapter 7	References	119
Appendix 1	Equations.....	150
Appendix 2	Raw data.....	151

Abstract

To repair massive bone defects caused by disease and trauma, a bone grafting procedure is required. The limitations associated with the use of autografts (tissue grafts from one point to another of the same individual's body) and allografts (tissue grafts between genetically nonidentical individuals) have boosted the research and development of bone graft substitutes.

Calcium phosphate cement (CPC) is a promising bone graft substitute because of its bioactivity, osteoconductivity and bone replacement capability. However, difficulties with injectability and slow resorption rate have limited the wider applications of CPC. To overcome these limitations, premixed and injectable calcium deficient apatite biocement (cd-AB) were prepared in the initial phase of this study. Using a non-aqueous solution as the liquid phase, the resulting premixed cd-AB had the advantage of remaining stable in the syringe and only hardened following delivery to the defect site. As well, when injected into an aqueous environment, this premixed cd-AB exhibited improved washout resistance when compared to the conventional cd-AB using water as the liquid phase. However, the premixed cd-AB required a longer setting time and developed a reduced compressive strength compared to the conventional cd-AB. The hydration products of premixed cd-AB were a mixture of calcium deficient hydroxyapatite (cd-HA) and PLA. *In vitro* Tris-HCl immersion tests demonstrated that the premixed cd-AB was degradable. The results revealed

that the premixed cd-AB was cytocompatible and no adverse effects were observed after attachment and proliferation of MG-63 osteoblast-like cells *in vitro*. The most distinct advantages of premixed and injectable PLA-modified cd-AB were its excellent washout resistance and *in vitro* degradability, suggesting that it may be a promising candidate for future bone reconstruction.

In recent years, bone tissue engineering has emerged as a promising approach for the repair of bone damage and defects. In this approach, a scaffold is normally used alone or in combination with growth factors and/or cells to guide bone regeneration. Among the synthetic polymers used as scaffold materials, poly(ϵ -caprolactone) (PCL) has been widely used given its excellent biocompatibility and ease of processing. However, the use of PCL scaffolds is limited as a consequence of potential drawbacks including a slow degradation rate and their hydrophobic surface. These disadvantages may be overcome by incorporating additional natural polymer or inorganic fillers into the PCL matrix.

In the second section of this study, porous scaffolds of zein/PCL biocomposite were fabricated and characterized. These scaffolds were prepared using the particulate leaching method with sodium chloride particles as porogen. Porous biocomposite scaffolds with porosity around 70% and well-interconnected network were obtained. The incorporation of zein into PCL led to an improvement of the surface hydrophilicity as confirmed by the results of water contact angle measurement.

Following immersion in a phosphate buffered saline solution (PBS) *in vitro* for 28 days, it was observed that the zein/PCL scaffolds degraded more rapidly than the PCL scaffolds and the degradation rate could be controlled by adjusting the amount of zein in the composite. These results demonstrated the potential of the zein/PCL biocomposite scaffolds to be exploited in tissue engineering strategies for the repair of bone defects.

In the final section of this study, porous scaffolds using a magnesium phosphate (MP)/PCL biocomposite were developed for bone tissue engineering applications. The composite scaffolds were fabricated by the particulate leaching method again using sodium chloride particles as porogen. The resulting scaffolds had interconnected macroporous structure with porosity around 73%. The surface hydrophilicity of the scaffolds was enhanced by the incorporation of MP component and confirmed by water contact angle measurement. The results from subsequent *in vitro* degradation experiments showed that the MP/PCL composite scaffolds degraded faster than PCL scaffolds in a PBS solution. An additional benefit was that the degradation rate of the scaffolds could be tuned by adjusting the content of MP component in the composite. These results indicated that the MP/PCL composite scaffolds have potential application in bone tissue engineering.

Declaration

I certify that this work contains no material which has been accepted for the award of any other degree or diploma in any university or other tertiary institution and, to the best of my knowledge and belief, contains no material previously published or written by another person, except where due reference has been made in the text. In addition, I certify that no part of this work will, in the future, be used in a submission for any other degree or diploma in any university or other tertiary institution without the prior approval of the University of Adelaide and where applicable, any partner institution responsible for the joint-award of this degree.

I give consent to this copy of my thesis when deposited in the University Library, being made available for loan and photocopying, subject to the provisions of the Copyright Act 1968.

The author acknowledges that copyright of published works contained within this thesis resides with the copyright holder(s) of those works.

I also give permission for the digital version of my thesis to be made available on the web, via the University's digital research repository, the Library catalogue and also through web search engines, unless permission has been granted by the University to restrict access for a period of time.

SIGNED:

DATE:

Acknowledgement

I owe many thanks to my principal supervisor Dr. Yung Ngothai who has provided guidance and encouragement throughout my PhD studies. I am particularly grateful to my external supervisor Prof. Changsheng Liu for providing the opportunity of studying in his research group in East China University of Science and Technology. I would like to thank A/Prof. Jie Wei for his advice, guidance and encouragement. I would also like to thank A/Prof. Brian O'Neill for his support.

I want to thank all members from Prof. Liu's research group for their support. I would like to thank Mr. Yuequn Wu, Ms. Wei Tang, Mr. Xiangde Li and Ms. Yingmei Zhao for their help with the experiments.

I would like to thank Dr. Joan Thomas for her advice. I would also like to thank Ms. Aoife McFadden for her help with the scanning electron microscopy and micro-CT.

Finally, I would like to express my deepest gratitude to my parents and my husband Milan for their love, encouragement and ongoing support.

爸爸妈妈，谢谢你们！

List of Publications

Journal papers

F. Wu, Y. Ngothai, J. Wei, C. Liu, B. O'Neill, Y. Wu. Premixed, injectable PLA–modified calcium deficient apatite biocement (cd-AB) with washout resistance. *Colloids and Surfaces B: Biointerfaces*, 2012, 92, 113–120.

F. Wu, J. Wei, C. Liu, B. O'Neill, Y. Ngothai. Fabrication and properties of porous scaffold of zein/PCL biocomposite for bone tissue engineering. *Composites: Part B*, 2012, 43, 2192–2197.

F. Wu, C. Liu, B. O'Neill, J. Wei, Y. Ngothai. Fabrication and properties of porous scaffold of magnesium phosphate/polycaprolactone biocomposite for bone tissue engineering. *Applied Surface Science*, 2012, 258, 7589–7595.

Conference paper

F. Wu, Y. Ngothai, C. Liu, J. Wei, B. O'Neill, R. Musgrove. Preparation and characterization of macroporous magnesium phosphate scaffold for bone regeneration. CHEMECA 2011, Sydney, Australia, September 2011.

Conference abstract

F. Wu, Y. Ngothai, C. Liu, J. Wei, B. O'Neill, R. Musgrove. PLA–modified magnesium phosphate bone cement with anti-washout property and degradability. CHEMECA 2011, Sydney, Australia, September 2011.

List of Figures

Figure 3.1 Behaviour of cement pastes after 5-min immersion in deionized water at 37 °C: (A) conventional cd-AB and (B) premixed cd-AB (prepared with 20% PLA-NMP solution).	43
Figure 3.2 The effect of P/L ratio on the setting time and compressive strength of the different cements	44
Figure 3.3 XRD patterns of the cements after hardening for 3 days: (A) premixed cd-AB and (B) conventional cd-AB.....	46
Figure 3.4 FTIR spectra of (A) conventional cd-AB after hardening for 3 days, (B) PLA and (C) premixed cd-AB after hardening for 3 days.	47
Figure 3.5 SEM micrographs of the fracture surface of cements after hardening for 3 days: (A) premixed cd-AB and (B) conventional cd-AB.....	49
Figure 3.6 Weight loss ratios of the different cements after immersion in Tris-HCl solution for different time.	52
Figure 3.7 Variations in the pH value of Tris-HCl solution after the immersion of different cements.	53
Figure 3.8 SEM micrographs of premixed cd-AB samples after immersion in Tris-HCl solution for (A and B) 1 day and (C and D) 28 days.	54
Figure 3.9 MTT assay for proliferation of MG-63 cells cultured on different cements at 3 and 5 days of incubation.....	56
Figure 3.10 SEM micrographs of MG-63 cells attached to: (A and B) conventional	

cd-AB; (C and D) premixed cd-AB.	57
Figure 3.11 Schematic representation of the hardening process of premixed cd-AB	59
Figure 4.1 Macroscopic image of the zein/PCL-40 scaffold.....	71
Figure 4.2 SEM images of the cross-sectional morphology of (A and B) PCL scaffold and (C and D) zein/PCL-40 scaffold.....	72
Figure 4.3 Micro-CT visualizations of the zein/PCL-40 scaffold: (A) 3D model and (B) semi-transparent overlay of a cross-section of the 3D model (the overlapping area is shown in light blue).....	74
Figure 4.4 FTIR spectra: (A) PCL scaffold, (B) zein powder, (C) zein/PCL-40 scaffold, (D) zein/PCL-40 scaffold after immersion in PBS for 14 days and (E) zein/PCL-40 scaffold after immersion in PBS for 28 days.....	76
Figure 4.5 Compressive stress-strain curves of the different scaffolds.....	78
Figure 4.6 Water contact angles of the different scaffolds.	79
Figure 4.7 Weight loss of the different scaffolds during the immersion period.....	81
Figure 4.8 The pH variations of PBS during the immersion period.....	82
Figure 4.9 SEM images of the surface morphology of the zein/PCL-40 scaffolds: (A and B) before immersion and (C and D) after immersion in PBS for 28 days.	83
Figure 5.1 Micro-CT 3D reconstruction model of the MP/PCL-40 scaffold.....	95
Figure 5.2 Pore size distribution of the MP/PCL-40 scaffold.	97
Figure 5.3 Micro-CT visualizations of a cross-section of MP/PCL-40 scaffold: (A) positive image (gray: scaffold; black: pore) and (B) negative image (black: scaffold;	

white: pore). 98

Figure 5.4 SEM images of the cross-sectional morphology of MP/PCL-40 scaffold:

(A) macropores larger than 200 μm and (B) macropores less than 10 μm 100

Figure 5.5 XRD patterns of (A) MP particles, (B) PCL, (C) MP/PCL-40 scaffold, (D)

MP/PCL-40 scaffold after immersion in PBS for 14 days and (E) MP/PCL-40 scaffold

after immersion in PBS for 28 days. 101

Figure 5.6 Compressive stress–strain curves of the different scaffolds. 103

Figure 5.7 Water contact angles of the different scaffolds. 104

Figure 5.8 Weight losses of the different scaffolds during the immersion period... 106

Figure 5.9 SEM images of the surface morphology of MP/PCL-40 scaffolds: (A and B)

before immersion and (C and D) after immersion in PBS for 28 days. 107

List of Tables

Table 2.1 Principal calcium phosphate compounds [26, 27].	8
Table 2.2 Formulations of some premixed CPCs.	16
Table 2.3 Synthetic biodegradable polymers.	22
Table 3.1 Injectability of premixed cd-AB pastes made with different liquids and P/L ratios.	50
Table 4.1 Compositions and porosities of the PCL/zein composite scaffolds.	75
Table 5.1 Compositions and porosities of the MP/PCL composite scaffolds.	96

List of Abbreviations

ANOVA	analysis of variance
cd-AB	calcium deficient apatite biocement
CPC	calcium phosphate cement
DMSO	dimethyl sulfoxide
ECM	extracellular matrix
FBS	fetal bovine serum
FDA	Food and Drug Administration
FTIR	Fourier transform infrared
HA	hydroxyapatite
HCA	hydroxycarbonate apatite
HPMC	hydroxypropyl methylcellulose
hMSCs	human mesenchymal stem cells
LPR	liquid-to-powder ratio
micro-CT	micro-computed tomography
MgO	magnesium oxide
MP	magnesium phosphate
MPC	magnesium phosphate cement
MTT	methyl thiazolyl tetrazolium
NMP	N-methyl-2-pyrrolidone
OD	optical density
PDLA	poly(D-lactide)
PDLLA	poly(DL-lactide)
PLLA	poly(L-lactide)
P/L	powder-to-liquid
PBS	phosphate buffer saline
PEG	polyethylene glycol

PHA	precipitated hydroxyapatite
PLA	polylactide
PCL	polycaprolactone
PTFE	polytetrafluoroethylene
RH	relative humidity
rpm	revolutions per minute
SBF	simulated body fluid
SD	standard deviation
SEM	scanning electron microscopy
TCP	tissue culture polystyrene
TCP	tricalcium phosphate
Tris	tris(hydroxymethyl)aminomethane
WCA	water contact angle
XRD	X-ray diffraction